[go: up one dir, main page]

AU2001249835A1 - Diagnosis and treatment of alzheimer's disease - Google Patents

Diagnosis and treatment of alzheimer's disease

Info

Publication number
AU2001249835A1
AU2001249835A1 AU2001249835A AU4983501A AU2001249835A1 AU 2001249835 A1 AU2001249835 A1 AU 2001249835A1 AU 2001249835 A AU2001249835 A AU 2001249835A AU 4983501 A AU4983501 A AU 4983501A AU 2001249835 A1 AU2001249835 A1 AU 2001249835A1
Authority
AU
Australia
Prior art keywords
alzheimer
diagnosis
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249835A
Inventor
Kathryn L. Durham
David L. Friedman
Herath Mudiyanselage Athula Chandrasiri Herath
Lida H. Kimmel
Rajesh Bhikhu Parekh
David M. Potter
Christian Rohlff
B. Michael Silber
Thomas R. Stiger
P. Trey Sunderland
Robert Reid Townsend
Frost White
Stephen A. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Pfizer Inc
Original Assignee
Pfizer Corp Belgium
Oxford Glycosciences UK Ltd
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Oxford Glycosciences UK Ltd, Pfizer Inc filed Critical Pfizer Corp Belgium
Publication of AU2001249835A1 publication Critical patent/AU2001249835A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001249835A 2000-04-03 2001-04-03 Diagnosis and treatment of alzheimer's disease Abandoned AU2001249835A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19450400P 2000-04-03 2000-04-03
US60/194,504 2000-04-03
US25364700P 2000-11-28 2000-11-28
US60/253,647 2000-11-28
PCT/US2001/010908 WO2001075454A2 (en) 2000-04-03 2001-04-03 Diagnosis and treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2001249835A1 true AU2001249835A1 (en) 2001-10-15

Family

ID=26890092

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249835A Abandoned AU2001249835A1 (en) 2000-04-03 2001-04-03 Diagnosis and treatment of alzheimer's disease

Country Status (5)

Country Link
US (2) US20020164668A1 (en)
EP (1) EP1325338A2 (en)
JP (1) JP2004505609A (en)
AU (1) AU2001249835A1 (en)
WO (1) WO2001075454A2 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160423A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1536 daltons
US6627606B2 (en) * 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1465 daltons
US6627608B2 (en) 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons
US7008800B2 (en) * 2001-04-30 2006-03-07 Artemis Proteomics, Ltd. Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons
US20020160420A1 (en) * 2001-04-30 2002-10-31 George Jackowski Process for diagnosis of physiological conditions by characterization of proteomic materials
US6890763B2 (en) * 2001-04-30 2005-05-10 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons
US20040198950A1 (en) * 2001-04-30 2004-10-07 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons
US7015004B2 (en) * 2001-11-23 2006-03-21 Syn X Pharma, Inc. Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance
US6599877B2 (en) 2001-04-30 2003-07-29 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1020 daltons
SG121733A1 (en) * 2001-10-03 2006-05-26 Pfizer Prod Inc Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2003032894A2 (en) * 2001-10-12 2003-04-24 Pfizer Products Inc. Method of monitoring neuroprotective treatment
US7314762B2 (en) * 2001-11-21 2008-01-01 Nanogen, Inc. Apolipoprotein biopolymer markers indicative of insulin resistance
US7132244B2 (en) 2001-11-21 2006-11-07 Syn X Pharma, Inc. Betaine/GABA transport protein biopolymer marker indicative of insulin resistance
US7052849B2 (en) * 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
US7026129B2 (en) * 2001-11-23 2006-04-11 Syn X Pharma, Inc. IG lambda biopolymer markers predictive of Alzheimers disease
WO2003046566A2 (en) * 2001-11-23 2003-06-05 Syn.X Pharma, Inc. Pedf biopolymer markers predictive of alzheimers disease
US7074576B2 (en) * 2001-11-23 2006-07-11 Syn X Pharma, Inc. Protein biopolymer markers indicative of alzheimer's disease
US7179605B2 (en) * 2001-11-23 2007-02-20 Nanogen Inc. Fibronectin precursor biopolymer markers indicative of alzheimer's disease
US7125678B2 (en) * 2001-11-23 2006-10-24 Nanogen, Inc. Protein biopolymer markers predictive of type II diabetes
US20030100009A1 (en) * 2001-11-23 2003-05-29 George Jackowski Inter alpha trypsin inhibitor biopolymer markers indicative of insulin resistance
US20030113808A1 (en) * 2001-12-13 2003-06-19 George Jackowski Apolipoprotein biopolymer markers predictive of alzheimers disease
ES2215957T3 (en) * 2002-08-01 2004-10-16 Mtm Laboratories Ag METHOD FOR DIAGNOSIS BASED ON A SOLUTION.
DE60333608D1 (en) * 2002-08-23 2010-09-09 Bayer Schering Pharma Ag Biomarker for the diagnosis of Alzheimer's
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US20070031908A1 (en) * 2003-03-18 2007-02-08 Norbert Lamping Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection reagents
WO2004111233A1 (en) * 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
EP1684692A2 (en) * 2003-10-29 2006-08-02 The Johns Hopkins University Pigment epithelium-derived factor, novel biological activity and methods of use
AU2005221187B2 (en) 2004-03-10 2011-09-01 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
JP4654418B2 (en) 2004-03-31 2011-03-23 独立行政法人産業技術総合研究所 Epithelial cell growth promoter
WO2006005591A1 (en) * 2004-07-12 2006-01-19 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
WO2006029838A2 (en) * 2004-09-14 2006-03-23 Geneprot Inc. Secreted polypeptide species involved in alzheimer’s disease
WO2006069739A2 (en) * 2004-12-27 2006-07-06 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
WO2006074787A2 (en) * 2004-12-27 2006-07-20 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
US20080307537A1 (en) * 2005-03-31 2008-12-11 Dana-Farber Cancer Institute, Inc. Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CN101267829A (en) * 2005-06-24 2008-09-17 卡迪拉保健公司 Thrombospondin-1 derived peptides and methods of treatment
JP5329961B2 (en) * 2005-09-06 2013-10-30 トリニティー セラピューティクス インコーポレイテッド Methods for treating immune-mediated neurological diseases
KR101439828B1 (en) 2005-11-30 2014-09-17 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
JP5475994B2 (en) * 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド Anti-Aβ globulomer antibody, antigen-binding portion thereof, corresponding hybridoma, nucleic acid, vector, host cell, method for producing said antibody, composition comprising said antibody, use of said antibody and method of using said antibody.
US20070166765A1 (en) * 2006-01-16 2007-07-19 Christian Rohlff Protein isoforms and uses thereof
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
JP5144499B2 (en) * 2006-03-31 2013-02-13 中外製薬株式会社 Antibody modification method for purifying bispecific antibodies
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) * 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
DK2202245T3 (en) * 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
ES2566957T3 (en) * 2007-09-26 2016-04-18 Chugai Seiyaku Kabushiki Kaisha Constant region of modified antibody
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI682995B (en) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 Antibody constant region alteration
JP5837821B2 (en) 2009-09-24 2015-12-24 中外製薬株式会社 Antibody constant region variants
WO2011108714A1 (en) 2010-03-04 2011-09-09 中外製薬株式会社 Antibody constant region variant
ES2684475T3 (en) 2010-04-15 2018-10-03 Abbvie Inc. Proteins that bind to beta amyloid
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
PH12013500974A1 (en) 2010-11-17 2013-07-08 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
MX349057B (en) 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT THAT INDUCES CYTOTOXICITY.
US9839671B2 (en) 2012-01-13 2017-12-12 The University Of Birmingham Peptide and uses therefor
GB2515334A (en) * 2013-06-20 2014-12-24 Neuro Bio Ltd Biomarkers for alzheimer's Disease
SG10201803449VA (en) 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
CN105334300A (en) * 2014-08-01 2016-02-17 沈德铭 Rapid method for screening treatment effectiveness of biological source substance
JP7082484B2 (en) 2015-04-01 2022-06-08 中外製薬株式会社 Method for Producing Polypeptide Heterogeneous Multimer
WO2017115773A1 (en) 2015-12-28 2017-07-06 中外製薬株式会社 Method for promoting efficiency of purification of fc region-containing polypeptide
UA126900C2 (en) 2016-04-28 2023-02-22 Чугаі Сейяку Кабусікі Кайся ANTIBODY CONTAINING DRUG
JP6967206B2 (en) * 2017-07-13 2021-11-17 株式会社Mcbi Biomarkers for cognitive dysfunction diseases and methods for detecting cognitive dysfunction diseases using the biomarkers
JPWO2019088143A1 (en) 2017-11-01 2020-11-12 中外製薬株式会社 Antibody variants and isoforms with reduced bioactivity
CN113111874A (en) * 2021-04-01 2021-07-13 上海市第一人民医院 Rapid classification method for lateral images of lumbar vertebrae

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US5272055A (en) * 1991-12-24 1993-12-21 The University Of Kentucky Research Foundation Detection of Alzheimer's disease and other diseases using a photoaffinity labeling method
US5429947A (en) * 1992-06-17 1995-07-04 Merril; Carl R. Diagnosing Alzheimer's disease and schizophrenia
CA2218599A1 (en) * 1995-04-19 1996-10-24 Acorda Therapeutics Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same
EP0910641A1 (en) * 1997-02-13 1999-04-28 Smithkline Beecham Plc Neural cell adhesion molecule splicing variants
WO1998040748A1 (en) * 1997-03-14 1998-09-17 Neuromark Diagnosing neurologic disorders
CA2328992A1 (en) * 1998-04-27 1999-11-04 Northwest Hospital Nr-cam gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors

Also Published As

Publication number Publication date
US20020164668A1 (en) 2002-11-07
US20070015217A1 (en) 2007-01-18
EP1325338A2 (en) 2003-07-09
WO2001075454A2 (en) 2001-10-11
JP2004505609A (en) 2004-02-26
WO2001075454A3 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
HUP1500560A2 (en) Thioflavin derivatives and their use in diagnosis and treatment of alzheimer's disease
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
AU2002323258A1 (en) Diagnosis and treatment of vascular disease
AU2002367535A1 (en) Diagnosis and treatment of vascular disease
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AU2002239765A1 (en) Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease
AU2001236592A1 (en) Methods for diagnosis of alzheimer's disease
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
AU2002326813A1 (en) Diagnosis and treatment of vascular disease
AU2002302238A1 (en) A method of treatment of alzheimer's disease and device therefor
AU2001257406A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
AU2003248660A1 (en) Treatment of vascular dysfunction and alzheimer's disease
AU2002341880A1 (en) Diagnosis and treatment of vascular disease
AU2002341604A1 (en) Diagnosis and treatment of vascular disease
AU2002312667A1 (en) Individualization of therapy with alzheimer's disease agents
PL377110A1 (en) Prevention and treatment of alzheimer's disease
AU2001253024A1 (en) Diagnosis and treatment of gastrointestinal disease
GB9908059D0 (en) Diagnosis and treatment of diseases
AU2002319591A1 (en) Diagnosis and treatment of vascular disease
HK1058546A (en) Diagnosis and treatment of alzheimer's disease